Afamelanotide Guide

Afamelanotide is the linear analogue of alpha-melanocyte stimulating hormone (α-MSH) — a potent melanocortin receptor 1 (MC1R) agonist approved by the FDA and EMA as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic phototoxicity disorder.

Administered as a 16 mg subcutaneous biodegradable implant every 60 days, afamelanotide provides sustained MC1R stimulation that promotes melanogenesis (skin darkening) and UV photoprotection. Also known as Melanotan I, it is distinct from Melanotan II (bremelanotide/PT-141) and remains the only FDA-approved melanocortin drug for a skin condition.

Track your protocol with Shotlee.

Afamelanotide is a 13-amino-acid linear peptide analog of α-MSH with a substitution at position 4 (Phe→D-Phe) that enhances receptor binding affinity and metabolic stability compared to the native hormone.

Its primary pharmacological target is Melanocortin Receptor 1 (MC1R), expressed on melanocytes — the pigment-producing cells of the skin. When afamelanotide binds MC1R, it activates adenylate cyclase (cAMP pathway), triggering: (1) Upregulation of tyrosinase — the rate-limiting enzyme in eumelanin synthesis.

This drives production of eumelanin ( brown/black pigment) rather than phaeomelanin (red/yellow pigment). Eumelanin is significantly more photoprotective than phaeomelanin, as it functions as a UV filter within the skin.

(2) Increased melanosome production and transfer — melanosomes (pigment organelles) are synthesized in greater quantity and transferred more efficiently to keratinocytes, providing broader UV photoprotection across the skin surface.

(3) DNA damage response activation — MC1R signaling activates nucleotide excision repair (NER) pathways independently of pigmentation, reducing UV-induced DNA strand breaks and photoproduct accumulation.

This dual mechanism — UV filtering through pigmentation AND enhanced DNA repair — makes MC1R activation particularly effective at preventing UV-induced cellular damage. The 16 mg biodegradable implant (Scenesse) provides sustained MC1R stimulation for 60 days via slow peptide release, producing stable pigmentation and photoprotection throughout the high-sun-exposure summer months.

This is why EPP patients — who experience severe phototoxic pain from even brief sun exposure — can tolerate significantly longer outdoor exposure while on Scenesse.

Erythropoietic protoporphyria (EPP) is a rare inherited disorder caused by mutations in FECH (ferrochelatase) — the enzyme that inserts iron into protoporphyrin IX to form heme.

Without functional FECH, protoporphyrin IX accumulates in red blood cells, plasma, and skin. When protoporphyrin is activated by visible light (400–420 nm Soret band), it generates reactive oxygen species that cause severe phototoxic skin pain, burning, and swelling.

Patients with EPP can experience excruciating pain within minutes of sun exposure, severely limiting outdoor activity and quality of life. Scenesse (afamelanotide) provides EPP photoprotection by increasing eumelanin content in the skin — reducing the proportion of visible light that reaches protoporphyrin in the skin.

Phase 3 clinical trials demonstrated Scenesse allowed EPP patients to spend significantly more time in direct sunlight without phototoxic reactions (median improvement +6 hours/month in summer). FDA approved Scenesse in 2019; EMA approved in 2014.

Off-label applications: afamelanotide (as research-grade Melanotan I, distinct from pharmaceutical Scenesse) is used off-label for: (1) Solar urticaria — a related photodermatosis where skin proteins denature with UV exposure; melanogenesis provides similar photoprotection.

(2) Polymorphous light eruption (PLE) — MC1R activation reduces PLE susceptibility. (3) Vitiligo — early research suggests MC1R stimulation may promote repigmentation. (4) Skin darkening/tanning without UV exposure — the most common off-label use; afamelanotide produces a natural-appearing tan without sun exposure, appealing for cosmetic purposes.

Track afamelanotide implant dates, pigmentation progress, and sun tolerance data in Shotlee for a complete protocol record.

Afamelanotide (Melanotan I) and Melanotan II (MT-II, precursor to bremelanotide/PT-141) are structurally related melanocortin peptides with critically different receptor selectivity profiles and clinical applications.

Afamelanotide (MT-I): a 13-amino-acid linear peptide that is primarily a selective MC1R agonist. MC1R is expressed predominantly on melanocytes — so afamelanotide produces primarily skin pigmentation effects with minimal systemic side effects.

It also has some MC3R activity (anti-inflammatory) and modest MC4R activity (appetite regulation) but these are secondary. FDA/EMA approved as Scenesse for EPP. Melanotan II (MT-II): a cyclic 7-amino-acid peptide that is a non-selective melanocortin agonist activating MC1R, MC3R, MC4R, and MC5R.

MC4R activation in the hypothalamus produces the strong sexual arousal and spontaneous erection effects that made MT-II well-known in biohacking circles. MC3R activation contributes to appetite suppression.

The non-selective MC4R activity also causes significant side effects: nausea, facial flushing, spontaneous erections, yawning, and stretching. Bremelanotide (PT-141/Vyleesi) is a more stable derivative of MT-II approved for hypoactive sexual desire disorder in women.

In summary: afamelanotide for photoprotection/pigmentation with a favorable side effect profile; Melanotan II for sexual enhancement with a harsher side effect profile. They should not be confused — afamelanotide does not meaningfully activate MC4R and therefore does not produce the sexual side effects associated with Melanotan II.

Scenesse (afamelanotide 16 mg) is administered as a small, solid, biodegradable implant — not a conventional injection.

The implant is a cylindrical rod approximately 1.7 cm long and 3.5 mm in diameter, composed of afamelanotide in a poly(DL-lactide) biodegradable polymer matrix. The polymer slowly degrades over 60 days, releasing afamelanotide at a controlled rate to maintain therapeutic plasma concentrations.

Insertion procedure: performed in a clinical setting (dermatologist office or EPP specialist clinic). A topical or local anesthetic is applied to the insertion site (typically the sub-navel abdominal skin).

A trocar or applicator delivers the implant subcutaneously. The procedure takes 5–10 minutes; no sutures are required (the small wound closes naturally). The implant is not palpable or visible beneath the skin.

After insertion: some patients experience mild insertion site reactions (bruising, discomfort) for 2–5 days. Pigmentation begins within 2–5 days as MC1R stimulation initiates melanogenesis. Maximal pigmentation is reached at 2–3 weeks and maintained for approximately 60 days before the implant is fully degraded.

For EPP treatment: implants are administered every 60 days during the spring/summer high-risk period (typically 3–4 implants per year). For off-label use with research-grade afamelanotide peptide: it is most commonly injected SC at lower doses (0.5–1 mg per dose) rather than as the implant formulation.

Afamelanotide has a well-characterized safety profile from Phase 3 clinical trials and post-marketing surveillance in EPP patients.

Common side effects (reported in >10% of trial participants): nausea (most common, typically transient in days 1–3 after implant insertion), headache, fatigue, and injection/implant site reactions (bruising, discomfort, minor swelling).

Skin-related: increased pigmentation as expected (the therapeutic mechanism); potential for uneven tanning or pigmentary changes in moles/nevi — patients should monitor any pigmented lesions and report changes.

Dermatologists recommend regular full-body skin checks while on Scenesse. Less common: dizziness, somnolence, and rare episodes of nausea/vomiting at higher doses. Importantly: afamelanotide does not cause the sexual side effects (spontaneous erections, libido changes) associated with Melanotan II, because it lacks significant MC4R activity.

No significant effects on blood pressure, heart rate, or reproductive hormones have been observed in trials. Melanoma concern: theoretically, MC1R stimulation that accelerates melanogenesis could be a concern in patients with melanoma risk.

However, Phase 3 trials showed no increase in atypical nevi or melanoma incidence. The FDA prescribing information recommends full-body skin examination before each implant and regular monitoring of pigmented lesions.

For EPP patients, the benefit of preventing phototoxic pain episodes significantly outweighs the theoretical melanoma risk concern.